Albireo Pharma — Biodel — Merger or Acquisition (October 2016)
43 slides from Albireo Pharma's merger presentation, Oct 11, 2016
Slide 1: Biodel Inc and Albireo Limited Share Exchange Agreement
Exhibit 99.1 Biodel Inc and NASDAQ: BIOD Albireo ? October Limited 11, Share 2016 Exchange Agreement
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Certain amended, therefore, publicly “expects,” “intends,” harbor in approval may parties satisfy benefits uncertainties Albireo A4250 pivotal numbers the availability trial product comparable EA additional United whether timing reliable All obligation “Albireo” 2©2016 the cash Pharma for
Slide 3: Additional Information and Where to Find It
Additional This the Meeting TRANSACTION, THEY that and transaction SEC Participants with filed Biodel 3©2016 proposed all Biodel presentation the with www.sec.gov. CONTAIN Inc., with other Albireo proposed and the Information and may 100 the in relevant has transaction, SEC Solicitation Limited. rel
Slide 4: Biodel—Albireo Combined Company
Biodel—Albireo Existing Combined Biodel NASDAQ Corporate 4©2016 stockholders stockholder Albireo Albireo HQ cash ticker toLimited. balance investors symbol be Share vote located willExchange expected scheduled All own iscommitted planned in rights approximately Boston, to Agreement reserved. for to
Slide 5: Significant Projected Near-Term News Flow
Significant Event Elobixibat: A4250: 5©2016Projected Albireo FDA report News report JNDA meeting additional data Limited. Timing Flow data filing fromQ4 from and Q1 All planned pediatric 2016 Near-Term 2017 rights ongoing pivotal data reserved. Ph3 Milestones from trial Trial ongoing ininPFIC Japan
Slide 6: Hope for Children with Orphan Liver Diseases Through Bile Acid Modulation
Hope for Children with Orphan Liver Diseases Through Bile Acid Modulation
Slide 7: Albireo: Innovative Leader in Bile Acid Modulators
Innovative Albireo Leader Three Multiple Strong AstraZeneca Highly 7©2016clinical patent Albireo in experienced near-term the Science spinout development portfolio, assets, Limited. inflection +management backed including Deep with Allof Pipeline rights by orphan opportunities bile lead syndicate te
Slide 8: Deep Clinical Development Management Team
DeepClinical Ron President (President BMS Paresh MBChB, Chief Alexion, Per-Göran Cubist, (Co-founder) AstraZeneca, Kristina VP, AstraZeneca 8©2016 Development Cooper Biotech Medical Soni Albireo Euthymics, Torfgård, Amarin, FCP, and of Gillberg, Jan SVP, Santaris, Europe) Pharmacia, CEO and Officer
Slide 9: A Robust Pipeline
A Robust Lead A4250 PFIC Liver Additional Elobixibat Partnered IBAT Malabsorption Cholestyramine Preclinical Bile Inflammatory Modulators NASH Orphan GI 9©2016 Indication Acid Program: Diseases inhibitor Albireo Ph2 NKPipeline inChronic Programs: Clinical pediatric antagonist Japan/Seeking Bowel Ref
Slide 10: Investment Thesis
Pediatric Novel, A4250 Elobixibat Partnering Voucher ©2016 10 First-in-Class Albireo Novel NASH Orphan BAM partnering Bile Limited. Development Opportunities Acid Product in PPAR Japan All rights Candidate Ph3 (positive US/EU Provide reserved. CICA3384 Ph3 Foundation to Treat trial) Pediatric Multip
Slide 11: A4250 for Pediatric Orphan Liver Diseases
A4250Diseases Liver for Orphan Pediatric
Slide 12: A4250 Positioned to Become First Approved Drug
Positioned A4250 Multiple Elevated Positive The Orphan Composition Method *includes ©2016 12 market science… exclusivity Albireo designation of effects pediatric serum estimated use toopportunity… of Become for Limited. on bile period… matter orphan liver serum in H-W acids First PFIC to disease All
Slide 13: IBAT Inhibitors Reduce Bile Acids
~ 95%known Inhibitors Reduced Increased Decreased Serum *also ©2016 13 Bile of Albireo liver bile colonic selectively pruritus Acids asacids and Limited. apical secretion serum and (BA) reduce sodium-dependent decreased All bile pumped and rights BA acids motility re-uptake cholesterol; from reserve
Slide 14: PFIC: No Approved Drug Options
A4250 No Symptoms Median pruritus Treatment Medical: Often Survival ©2016 14 Approved leads Albireo Estimated onset relief off options: develop tolabel 2Drug is liver Limited. months the ~10,000 UDCA, to failure early Options goal address Severe All of inrifampin, PFIC byearly children for rights ag
Slide 15: Surgical PEBD Supports Rationale for IBAT Inhibition
Benefits Surgical PEBD Long-term One ©2016 15 Year normalizes Albireo procedure ofBefore benefits BileLimited. Diversion Surgery serum to of permanently PEBD All bile After Surgery rights include acids, Surgery reserved. divert Supports which sustained Bile bile indicates Acids Rationale flow reduct
Slide 16: A4250 Preclinical Proof of Principle
*16 Proof A4250 ?Preclinical 1000 300 350 800 250 400 20 Liver 0 150 *p< ALT: ALP: —— *p< **p< 600 ALT ofAlbireo Minimal ©2016 0.05Enzymes 100 200 * Principle 0.05 0.01 (U/L) and Cholestatic weeks Normal alanine alkaline200Early ALP *?7and Serum 50Clinical 4Limited. weeks (picomolar) Control (U/L) M
Slide 17: Phase 1 and Adult Cholangitis Study Data
1.5mg Study First Investigator-Initiated Cholangitis Crossover (cholestyramine Cohort ineffect Promising No A4250 Adults 6Datapediatric All 50% Strong Dose-related Second Evaluating the 1.5 ©2016 17 effect mg treated mean design, received study Albireo 3cohort mg on Data patients effect QD with pati
Slide 18: Ongoing Pediatric Phase 2 Study Design
618Four-week Ongoing Designed A4250 Key Diagnosis (e.g., Primary Number Events Secondary Pruritus Cohorts -Open Sprinkle Up toinclusion PFIC, label, 24 (SAE) parameters; 1-4 endpoints sites of formulation Phase subjects to of endpoints treatment-emergent Alagille dose complete Support repeated pruri
Slide 19: Ph2 Pediatric Study Outline
*19 Ph2 Pediatric ©2016 Wash-out Albireo Study: in Outline caseAll Limited. ofrights bile acid resin or other prohibited medication use of 7 days required PK reserved.
Slide 20: Patient Demographics and Dose Summary
Patient Albireo ©2016 20 Demographics Limited. andAllDose rights Summary reserved.
Slide 21: Ph2 Pediatric Study: Safety and Tolerability
Ph2AEs Favorable Primary Endpoint Adverse No ©2016 21 treatment-emergent dropouts Pediatric Albireo in Safety Events events Safety 4-week Study: Limited. generally and dosing Tolerability serious All mild period rights and adverse deemed Data reserved. transient events by investigator (SAE) to be li
Slide 22: Ph2 Primary Efficacy Endpoint: Serum Bile Acid Reduction
Ph2 No 218 151 Mean -66.4 *Percentage ± CONFIDENTIAL. 22Enrollment indicates Bile 213 78.7 Pediatric -135 dose baseline post-treatment difference Salt 220 61.9 -159 Standard (mg) 31% Export 291 criteria Study: 178 sBA -113 45% 0.3 (µmol/L) sBA ©2016 Pump 0.7 Error Primary (µmol/L) for 63% (µmol/L) 1
Slide 23: Similar Results When Outlier Removed
Similar Cohort mean CONFIDENTIAL. 23 measures 4Results (1.7 mg (nonresponder When sBA mean) ©2016 (µmol/L)—baseline Cohort removed, and Albireo Cohort 4 Outlier n=3) Limited. 3 (1.4 Excluded 226, mg Allpost-treatment mean) rights reserved. 75.3, difference -151 (-62% ± 16)
Slide 24: Robust Reduction in Serum Bile Acids in PFIC Patients
Ph2 Pediatric (including early Study: cohorts Particularly with subtherapeutic Robust Reduction doses) CONFIDENTIAL. in Serum Bile Acids©2016 in PFIC Albireo Patients Limited. Mean All sBArights Reduction reserved. PFIC (n=7) PFIC (n=6, Cohort 4 outlier excluded) Mean + SEM Mean + SEM Includes Cohor
Slide 25: Secondary Efficacy Endpoints
A4250 Cohort 0.01 Measure Pruritus Sleep Liver Mean ± CONFIDENTIAL. 25indicates mg/kg Biochemistry –change Dose Ph2 1PO-SCORAD Outcomes –Cohort Whitington VAS PO-SCORAD Standard Pediatric 0.03 0.3vs-1.41 mg Baseline 2 Cohort mg/kg Aligned ©2016 0.7 variable Error Study: ±0.03 +0.12 mg 1.10 0.06 -1.0
Slide 26: A4250 Staged Development Approach
A4250 Biliary Syndrome Alagille POC* (Primary Cirrhosis) Ph2 Ped. Development *POC= Disease ©2016 Cholangitis Sclerosing Primary 26 Ph2 Chol. in Albireo Staged (PRO) Proof Pruritus Adults Biliary in Children Liver of Atresia Clinical Limited. Cholestatic Concept Liver Pruritus Pivotal Disease Develo
Slide 27: Planned Pivotal Trial and Accelerated Approval Path
Subpart A4250 Seek Planned supported Secondary/Exploratory Enrollment Long-term Time Request 27 accelerated toPost-Approval PEBD, H primary forby Approval outcome criteria FDA PEBD time endpoint: approval meeting tostudy surgery for toexclude Long-Term liver endpoints: PFIC planned to for sBA data t
Slide 28: Correlation Between sBA and Pruritus Reduction
528 Correlation All 0lta2dp5Cohort -e—1 % Albireo CONFIDENTIAL.e5 sa51-4 e=0dc0.01 2re Between Clinical4s0ae7patients re 3b1©2016 in5Datacile 0Reduction e0Reinforces ad(n=15*) c2id SA 1ofV Albireo s *VASSerum scoreBile AllAcids sBA/Pruritus Limited.not rightsand available Link Reduction reserved. fo
Slide 29: Precedent for Biochemical Endpoints in Orphan Approvals
Precedent Intercept’s Albireo ALP Alexion’s Approval 29 working based Kanuma for OCAOrphan on for with for composite endpoints early-stage Approvals statistician LAL Deficiency on endpoint PBC percentage Using used by Biochemical alkaline ICPT of subjects to phosphatase qualify Endpoints achieving b
Slide 30: Competitor IBAT Inhibitor Data and Variability
Variability Highlight A4250 PFIC improve Subset Significant 12.1% Alagille Did 13 Following The Potent *various ©2016 30 weeks, Albireo not PSC Compound of Albireo meet PBC liver Shire patients PFIC-2 Need interim double the in reductions Approach 1° SBA Phase parameters first press Limited. for end
Slide 31: A4250 Multiple Pediatric Orphan Opportunities
A4250 A Multiple Pediatric Biliary Attractive Favorable *Estimated ©2016 31 Albireo Atresia Rare Cholestatic Compelling Orphan Competitive prevalence Diseases Pruritus Limited. Pricing Commercial data Landscape with All and derived rights NoReimbursement Approved reserved. Expected Opportunity based
Slide 32: Pipeline Programs
Pipeline Programs Elobixibat CIC Ph3 A3384 BAM Ph2 NASH Preclinical
Slide 33: Elobixibat: Blockbuster Potential in CIC
First oElobixibat Blockbuster The Composition *includes ©2016 33156% Strong market data… commercial exclusivity and Albireo dollar US Only estimated opportunity… sales Ph2b ofRx Large Limited. period… matter potential… potential market efficacy H-W Bowel-Acting toAll 2027*, growth PTE data Different
Slide 34: Elobixibat Licensed in Japan: Positive Phase 3
in Ph3 Elobixibat Licensed License Approximately Positive Primary All Change No EA Ph2b US/EU Ph3 *plus CONFIDENTIAL. 34 SAEs; Pharma secondary (US/EU (US): five Trial in follows Endpoint endpoint Phase toother substantially weekly complete primary expected EA In ex-licensee): efficacy 3Japan $31.1
Slide 35: A3384 BAM Positioned to Become First Approved Drug
*35 Positioned The Phase Designed BAM science… Earlier ©2016 2Albireo BAM p to <market to0.05 commercialdeliver exclusivityBecome Study generation opportunity… cholestyramine First Limited. period… potential… Drug formulation All oApproved Elevated Formulation rights directly Blockbuster proves rese
Slide 36: IBAT Inhibition Platform in NASH
15,00 IBAT Improved 30,00 35,00 LDL/HDL in *Ratio20,00 change % ** Placebo 0,00 Chey Reduction 2.0 Relative 0**p<0.05GLP1 NASH *Albireo *p<0.05 5,00 p<0.01 1.5et 25,00 1.5 * Cholesterol 10,00 al 15 *expression *p<0.05 Am of pmol/L Platform: *p<0.05 mg Relative 0.5 Baghdasaryan ©2016 36 Tnf-a Mcp1 0.
Slide 37: A4250 NASH Preclinical Data
IBAT Inhibitor A4250 10 Mean Presented p<0.05 OCA Kremoser Candidate ©2016 37 mg/kg, data Significant ±Albireo OCA SDSTAM™ at et enzymes, Screening 3 wks 2016 al. OCA Limited. 9th 10 NAS DDW Significantly Model JSH mg/kg, increased forReduction Single All Novel Meeting Matches 5rights wks cholestero
Slide 38: Summary
RRianci Alhirad&
Slide 39: Investment Thesis
Pediatric Novel, A4250 Elobixibat Partnering Voucher ©2016 39 First-in-Class Albireo Novel NASH Orphan BAM partnering Bile Limited. Development Opportunities Acid Product in PPAR Japan All rights Candidate Ph3 (positive US/EU Provide reserved. CICA3384 Ph3 Foundation to Treat trial) Pediatric Multip
Slide 40: Strong Patent and Regulatory Protections
Strong Est. liver Elobixibat Composition MOU A3384 CIC/IBS Formulation *H-W ©2016 40 H-W diseases IBAT PTE Patent Albireo USPTE* US Expiry for inhibitors (pending) of (pending) and Expiry one Limited. Matter + A4250 Regulatory Est. patent Est. to H-W February August September Orphan All treat US per
Slide 41: Significant Projected Near-Term News Flow
Significant Event Elobixibat: A4250: ©2016 41 Projected Albireo FDA report News report JNDA meeting additional data Limited. Timing Flow data filing fromQ4 from and Q1 All planned pediatric 2016 Near-Term 2017 rights ongoing pivotal data reserved. Ph3 Milestones from trial Trial ongoing ininPFIC Jap
Slide 42: Albireo: Innovative Leader in Bile Acid Modulators
Innovative Albireo Leader Three Multiple Funding Highly ©2016 42 clinical Albireo in experienced expected near-term the Science development assets Limited. toinflection +management (lead be Deep sufficient All Ph2 of Pipeline rights opportunities bile orphan team to acid reserved. + advance Experien
Slide 43: Thank you
Thank you BIOD ? October 11, 2016 NASDAQ: